This report reviews the treatment process of a patient with post-liver-transplant Candida aurisbloodstream infection, in which a clinical pharmacist was involved throughout. It explores the optimization of individualized treatment regimens for patients with post-liver-transplantCandida auris infections and identifies areas for clinical pharmacist intervention. The patient initially received empirical anti-infective therapy with vancomycin and meropenem, which proved ineffective. AfterCandida auris infection was confirmed via aspiration fluid analysis, treatment with caspofungin alone for 5 days still showed no improvement. The clinical pharmacist recommended switching to amphotericin B liposome in combination with caspofungin and adjusting the tacrolimus dose via therapeutic drug monitoring (TDM). The patient’s infection-related symptoms were relieved, blood cultures turned negative, and the tacrolimus dose reached the target range. This case reminds medical staff thatCandida auris infections in transplant patients should be identified as early as possible. For patients who do not respond well to caspofungin, the use of amphotericin B in combination may be considered for the treatment. Caspofungin affects tacrolimus blood concentration, and routine TDM is required in clinical application.

1. CristinaML,SpagnoloAM,SartiniM,et al.An overview onCandida aurisin healthcare settings[J].J Fungi (Basel),2023,9(9):913.DOI:10.3390/jof9090913.

2. 陈文倩,张雷,张弋,等.实体器官移植他克莫司个体化治疗专家共识[J].中国医院用药评价与分析,2021,21(12):1409-1424.ChenWQ,ZhangL,ZhangY,et al.Expert consensus on individual treatment of tacrolimus in solid organ transplantation[J].Evaluation and Analysis of Drug-Use in Hospitals of China,2021,21(12):1409-1424.DOI:10.14009/j.issn.1672-2124.2021.12.001.

3. SatohK,MakimuraK,HasumiY,et al.Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital[J].Microbiol Immunol,2009,53(1):41-44.DOI:10.1111/j.1348-0421.2008.00083.x.

4. 曲锐,卢鸿,贺云霞,等.耳念珠菌研究进展[J].中国抗生素杂志,2025,50(8):885-893.QuR,LuH,HeYX,et al.Advances in research onCandida auris[J].Chinese Journal of Antibiotics,2025,50(8):885-893.DOI:10.3969/j.issn.1001-8689.2025.08.003.

5. 中华医学会检验分会临床微生物学学组.成人耳念珠菌感染诊治防控专家共识[J].临床检验杂志,2020,38(8):564-570.Chinese Medical Association Laboratory Medicine Branch, Clinical Microbiology Group.Expert consensus on diagnosis, treatment and prevention ofCandida auris infection in adults[J].Journal of Clinical Laboratory Science,2020,38(8):564-570.DOI:10.13602/j.cnki.jcls.2020.08.02.

6. AslamS,RotsteinC,et al.Candidainfections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J].Clin Transplant,2019,33(9):e13623.DOI:10.1111/ctr.13623.

7. SabinoR,VeríssimoC,PereiraÁA,et al.Candida auris, an agent of hospital-associated outbreaks: which challenging issues do we need to have in mind?[J].Microorganisms,2020,8(2):181.DOI:10.3390/microorganisms8020181.

8. 全国医疗机构感染监测网,中华预防医学会医院感染控制分会,全国医院感染监控管理培训基地.耳念珠菌医院感染预防与控制专家共识[J].中华医学杂志,2025,105(23):1907-1917.National Healthcare-associated Infection Surveillance Network of China,Hospital Infection Control Branch of Chinese Preventive Medicine Association, andNational Training Base for Hospital Infection Control and Management.Consensus of experts on healthcare-associated infection prevention and control ofCandida auris[J].National Medical Journal of China,2025,105(23):1907-1917.DOI:10.3760/cma.j.cn112137-20250305-00528.

9. ElhajA,JawharD,ElfakiN.Successful management ofCandida auris external ventricular shunt infection: a case report[J].J Med Case Rep,2025,19(1):393.DOI:10.1186/s13256-025-05088-3.

10. 郝萌萌,郭丽萍,黄记水,等.新型冠状病毒共感染耳念珠菌患者临床结局评价[J].中华医院感染学杂志,2025,35(2):207-214.HaoMM,GuoLP,HuangJS,et al.Clinical treatment outcomes of patients with concurrent infections of SARS-CoV-2 andCandida auris[J].Chinese Journal of Nosocomiology,2025,35(2):207-214.DOI:10.11816/cn.ni.2025-240753.

11. RossZK,AlsayeghS,ZhaoY,et al.In vitroevolution of caspofungin resistance inCandidozyma auris via FKS1 hotspot I mutations results in moderate fitness trade-offs but no reduction in virulence[J].Microbiol Res,2025,301:128322.DOI:10.1016/j.micres.2025.128322.

12. ZhangY,ShenB,LiY,et al.Drug-drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with differentCYP3A5 genotypes[J].Ther Adv Drug Saf,2024,15:20420986241243165.DOI:10.1177/20420986241243165.

13. KimHY,BaldelliS,MärtsonAG,et al.Therapeutic drug monitoring of theEchinocandinantifungal agents: is there a role in clinical practice? A position statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology[J].Ther Drug Monit,2022,44(1):198-214.DOI:10.1097/FTD.0000000000000931.

14. MistroS,Maciel IdeM,de MenezesRG,et al.Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and Meta-analysis[J].Clin Infect Dis,2012,54(12):1774-1777.DOI:10.1093/cid/cis290.

15. 陈凡,胡述立,张韶辉,等.卡泊芬净相关肝损伤的真实世界研究[J].中国医院药学杂志,2021,41(13):1337-1340.ChenF,HuSL,ZhangSH,et al.Liver injury associated with caspofungin: a real-world study[J].Chinese Journal of Hospital Pharmacy,2021,41(13):1337-1340.DOI:10.13286/j.1001-5213.2021.13.12.

16. LiZ,CuiZ,XieD,et al.Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration[J].Front Pharmacol,2025,16:1632488.DOI:10.3389/fphar.2025.1632488.